Sugi Predict

Sugi Predict / Targets / CACNB4

CACNB4

Voltage-dependent L-type calcium channel subu · O00305 · CACNB4 on Sugi Atlas →

6,686 patent compounds predicted against CACNB4, 2,935 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL116362 SCHEMBL116362 0.45 11/20
SCHEMBL2585915 SCHEMBL2585915 0.51 8/20
SCHEMBL3354274 SCHEMBL3354274 0.62 7/20
SCHEMBL3357851 SCHEMBL3357851 0.54 7/20
SCHEMBL4750473 SCHEMBL4750473 0.52 7/20
SCHEMBL3350921 SCHEMBL3350921 0.49 7/20
SCHEMBL619154 SCHEMBL619154 0.41 7/20
SCHEMBL620978 SCHEMBL620978 0.40 7/20
SCHEMBL621013 SCHEMBL621013 0.40 7/20
SCHEMBL5428566 SCHEMBL5428566 0.52 6/20
SCHEMBL621555 SCHEMBL621555 0.39 6/20
SCHEMBL617973 SCHEMBL617973 0.38 6/20
SCHEMBL4405461 SCHEMBL4405461 0.55 5/20
SCHEMBL4399845 SCHEMBL4399845 0.54 5/20
SCHEMBL4967687 SCHEMBL4967687 0.51 5/20
SCHEMBL1810921 SCHEMBL1810921 0.51 5/20
SCHEMBL4399843 SCHEMBL4399843 0.50 5/20
SCHEMBL3477582 SCHEMBL3477582 0.47 5/20
SCHEMBL3353571 SCHEMBL3353571 0.47 5/20
SCHEMBL3248439 SCHEMBL3248439 0.45 5/20

Clinical trials — most relevant to CACNB4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of Pregabalin and Etoricoxib on Pain Alone Versus in Combination PHASE4UNKNOWN
Role of Intralipid in Management of Organophosphorus Poisoning PHASE2/PHASE3WITHDRAWN
4-Aminopyridine in Episodic Ataxia Type 2 PHASE2WITHDRAWN
Population Pharmacokinetic-pharmacodynamic (PK-PD) Modeling of Co-administered Gabapentin in Neuropathic Pain PHASE2COMPLETED
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients PHASE2WITHDRAWN
Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis PHASE2COMPLETED
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients PHASE2WITHDRAWN
Calcium Channel Blockade in Primary Aldosteronism PHASE2COMPLETED
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development nanRECRUITING
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services nanUNKNOWN
Genetic Determinants of Sudden Cardiac Death nanCOMPLETED
A Single Center Prospective Study in an Estimated 570 Patients Who Underwent Genetic Screening at UZ Brussel in the Context of a Primary Cardiac Arrhythmia. Patients Showing a Variant Class 3,4 or 5 in SCN4A or CLCN1 Will Undergo a Clinical and Electrophysiological Review After IC. nanNOT_YET_RECRUITING
A Natural History Study of RYR1-Related Disorders nanRECRUITING
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
Factors Affecting Salt Intake in Young Adults nanUNKNOWN
Multicenter Study of Patients With SHANK3 Mutations: Identification of Genes Modificators in Phelan-McDermid Syndrome (EUQ13) nanNOT_YET_RECRUITING
iCorMicA - Stratified Medicine in Angina nanRECRUITING
Sodium Channel Splicing in Heart Failure Trial nanCOMPLETED
MRI-phenotyping of Patients With Pathogenic Anoctamin 5 Variants nanRECRUITING
The Natural History of TRPV4 Neuropathy nanRECRUITING
Artificial Intelligence for the Prioritization of Genetic Background in Brugada Syndrome nanCOMPLETED
Evaluation of A Clinical Diagnostic Test for CRDS nanRECRUITING
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases nanUNKNOWN
Exploring the Genetics of Neuropathic Pain nanRECRUITING
Painful Channelopathies Study nanUNKNOWN
Pharmacogenetics and Cardiovascular Events nanCOMPLETED
Early Detection of Cardiomyopathy by Speckle Echo, High Sensitive Troponin and Cardiac Ryanodine Receptors nanUNKNOWN
Verapamil in Supraclavicular Brachial Plexus Block nanUNKNOWN
International CRDS Registry nanRECRUITING
Susceptibility Genes in Autism Spectrum Disorders nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CACNB4 binder may also engage these)

ProteinNameSimilarity
Q8R0S4 — 1.000 Q8R0S4 →
D4A055 — 1.000 D4A055 →
Q9MZL5 — 0.955 Q9MZL5 →
P54288 — 0.955 P54288 →
Q62599 — 0.950 Q62599 →
CACNB2 Voltage-dependent L-type calcium channel subunit beta-2 0.946 landscape →
Q8CJ19 — 0.946 Q8CJ19 →
F1QH17 — 0.945 F1QH17 →
Q8K4B0 — 0.945 Q8K4B0 →
Q13330 — 0.945 Q13330 →
G3MWR8 — 0.944 G3MWR8 →
P19517 — 0.943 P19517 →
Q5PYH5 — 0.940 Q5PYH5 →
Q8K4Q0 — 0.939 Q8K4Q0 →
Q8VGC3 — 0.937 Q8VGC3 →
RPTOR Regulatory-associated protein of mTOR 0.937 landscape →
Q9ERA0 — 0.936 Q9ERA0 →
Q7RTP6 — 0.935 Q7RTP6 →
Q61187 — 0.935 Q61187 →
Q9Y4J8 — 0.934 Q9Y4J8 →
Q12800 — 0.934 Q12800 →
Q811D0 — 0.933 Q811D0 →
Q62696 — 0.933 Q62696 →
Q8CC27 — 0.933 Q8CC27 →
Q9UPY8 — 0.933 Q9UPY8 →
A0A8C0TYJ0 — 0.933 A0A8C0TYJ0 →
Q3T174 — 0.932 Q3T174 →
Q6NZH6 — 0.932 Q6NZH6 →
Q7ZWU5 — 0.932 Q7ZWU5 →
Q7T2U9 — 0.931 Q7T2U9 →